Chief Medical Officer, Autoimmune & Oncology Leader

Immix Biopharma (Nasdaq: IMMX); Los Angeles (CA); On-site; USD 400,000 - 900,000; Full time

Job summary

Immix Biopharma is seeking a physician leader to serve as Chief Medical Officer. You will guide clinical development across autoimmune and oncology indications, interfacing with sites, CROs and investigators, and shaping the broader development strategy.

The ideal candidate has deep early-to-late-stage development experience, with a track record of advancing precision medicines and a rigorous scientific approach.

Qualifications

• MD/DO/MBBS with fellowship in medical hematology/oncology.
• Five or more years of FDA-facing clinical development experience.
• Deep knowledge of autoimmune diseases and oncology, including drug development paradigms and regulatory approaches.
• Outstanding written and verbal communication skills.
• Ability to drive collaboration and resolve conflicts across stakeholders.
• In-depth understanding of phase I–IV drug development.
• Passion for clinical development and precision medicine with external expert network.

Responsibilities

• Provide leadership to a cross-functional, matrix team of physicians, clinical scientists and other development teams.
• Contribute therapeutic area expertise to enhance trial design and execution.
• Oversee clinical development plans and regulatory documents.
• Lead IND, NDA, BLA submissions with regulatory agency interactions.
• Act as clinical lead for early development studies: design, protocol writing, monitoring and reporting.
• Build relationships with investigators and thought leaders with Medical Affairs collaboration.
• Support scientific advisory boards and external collaborations.

Skills

Medical leadership

Clinical development

Regulatory strategy

Cross-functional collaboration

IND/NDA expertise

Education

MD/MBBS/DO with hematology-oncology fellowship

Job description

Immix Biopharma is seeking a physician leader to serve as Chief Medical Officer. You will guide clinical development across autoimmune and oncology indications, interfacing with sites, CROs and investigators, and shaping the broader development strategy.

The ideal candidate has deep early-to-late-stage development experience, with a track record of advancing precision medicines and a rigorous scientific approach.